Johnson & Johnson (JNJ)
|Net Income (ttm)||17.77B|
|Trading Day||July 30|
|Day's Range||171.84 - 172.98|
|52-Week Range||131.09 - 173.38|
The healthcare giant has weathered much bigger storms in the past.
A House Oversight subcommittee sent a letter to Johnson & Johnson's (NYSE: JNJ) CEO Alex Gorsky asking for documents and information on any company plans to place a subsidiary into bankruptcy over talc ...
Women Cancer Victims Opposed to Johnson & Johnson's 'Texas Two-Step' Bankruptcy Ploy Urge Passage of Reforms Introduc...
WASHINGTON, July 29, 2021 /PRNewswire/ -- More than 30,000 women cancer victims would retain their constitutional right to have juries decide if talc in Johnson & Johnson's (NYSE:JNJ) baby products caus...
Investors should consider more than just the healthcare giant's impressive financial numbers when deciding whether to invest in its stock over the long term.
Shareholders bored by lagging returns might get some excitement in the near future.
The extension will give health workers six additional weeks to administer millions of doses of the single-shot vaccine.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
A Black women's advocacy group filed a lawsuit Tuesday accusing Johnson & Johnson of selectively marketing the company's talcum-based products, including Johnson's Baby Powder, to African-American women...
NEW BRUNSWICK, N.J., July 27, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Virtual Wells Fargo Healthcare Conference on Friday, September 10 th.
Pharma Heavyweights, Including Pfizer And JNJ Trying To Push Global Tax Deal Amid COVID-19 Role: WSJ
In the face of a comprehensive global tax agreement intended to inhibit tax avoidance opportunities, industry executives and lobbyists are mounting a quiet campaign to push back against the measure, the...
What healthcare executives are saying so far about the impact of the coronavirus variant on their businesses is reassuring.
J&J Snack Foods (JJSF) delivered earnings and revenue surprises of 91.14% and 3.57%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
The price action has tested resistance, while the option activity suggests that traders continue to both buy calls and sell puts.
Johnson & Johnson (NYSE: JNJ) shares have advanced almost 5% since the beginning of July 2021; the company reported better than expected second-quarter results this Wednesday and expects even better tre...
Financials, basic materials, energy sectors are stocks Neuberger Berman's Salzmann recommends
Eli Salzmann, portfolio manager of The Neuberger Berman Large Cap Value Fund, joins 'The Exchange' to discuss the future of the market with Kelly Evans. He values traditional financial and energy stocks...
Peak growth may be behind us, says Schroders' Ron Insana
Ron Insana, Schroders senior advisor, and Stephanie Link, HighTower chief investment strategist and portfolio manager, joins 'Power Lunch' to discuss the state of the market and their earnings expectati...
It was a jarring start to the week for Wall Street, with stocks in a seeming freefall as a rise in global Covid-19 cases, specifically the delta variant, had many wondering if the smooth economic recove...
J&J's smaller partner could benefit in a big way from the approval of a new version of blood cancer drug Darzalex.
Guillain-Barre syndrome (GBS) will be listed as a very rare side effect of Johnson & Johnson's (NYSE: JNJ) COVID-19 Vaccine. The warning will be included in the product information to raise awareness am...
The company recorded 164 million in COVID-19 vaccine sales in the second quarter, up 64% from the first, and aims to fetch $2.5 billion in sales by the end of the year.
Attorney generals of several states reach settlement deal with J&J (JNJ) and three drug distributors - MCK, CAH and ABC - related to thousands of opioid abuse litigations. Non-participating states may j...
Coronavirus variants will be the key variable.
It shouldn't impact the healthcare giant very much.
States reach deal to settle with opioid distributors, Johnson & Johnson
CNBC's Meg Tirrell joins Shep Smith to report on a $26 billion settlement between states and opioid distributors, as well as Johnson & Johnson. Not all states have agreed to accept the settlement.
States announce $26 billion settlement to resolve opioid lawsuits: RPT
Chris Meekins, Healthcare Policy Research Analyst at Raymond James, joins Yahoo Finance's Kristin Myers and Alexis Christoforous to discuss healthcare talks in Washington this week and the latest news o...
A group of state attorneys general unveiled on Wednesday a landmark, $26 billion settlement resolving claims that the three largest US drug distributors and drugmaker Johnson & Johnson helped fuel a dea...
Fauci: Vaccines are safe and effective against delta variant
"We just need to get more and more people vaccinated," Dr. Anthony Fauci, chief medical advisor to President Biden, tells 'Closing Bell.' He emphasizes the need for data-based conclusions, like the fact...
What did the stock market do today? It began to address the opioid crisis, it tuned in on Bitcoin and it saw a devastating Olympics loss.
Attorneys General propose a $26 billion global opioid settlement with the 'big three' drug distributors
A group of states Attorneys General announced a proposed $26 billion global settlement Wednesday that, if approved, will resolve claims against the "big three" drug distributors — McKesson Corporation, ...
J&J Shot Found to Raise Fewer Antibodies Against Delta Variant
Jul.21 -- Johns Hopkins Bloomberg School of Public Health Professor and Virologist Andrew Pekosz discusses the efficacy of the Johnson & Johnson Covid-19 vaccine against the delta variant. The Bloomberg...
The deal will resolve thousands of opioid crisis-related lawsuits.
States reach $26B settlement with opioid distributors and Johnson & Johnson
CNBC's Meg Tirrell reports on a settlement in a lawsuit against opioid distributors in the U.S.
Study shows Johnson & Johnson vaccine may be less effective against Delta variant
#Johnson&Johnson Dr. Amesh Adalja, Senior scholar Johns Hopkins center for health security, joins Yahoo Finance's Kristin Myers to discuss the latest on the coronavirus pandemic, vaccines and the Delta ...
As the Delta variant rapidly spreads across the U.S., accounting for 83% of the country's cases, a new study showed that neutralizing titers induced by Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine d...
Shares of Johnson & Johnson ( JNJ , Financial), one of Yacktman Asset Management (Trades, Portfolio)'s top 10 holdings, rose slightly above the flatline on Wednesday after reporting second-quarter earni...
J&J CFO: Not-for-Profit Vaccine Price Likely to End in 2021
Jul.21 -- Johnson & Johnson CFO Joseph Wolk discusses the efficacy of the company's Covid-19 vaccine against the delta variant, second-quarter results, and efforts to address damage claims over its talc...
Johnson & Johnson posted strong second-quarter results on Tuesday (July 21), beating Wall Street estimates as sales of beauty and skincare products begin to recover from COVID-19 and patients resume pre...
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the S... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2020, JNJ's revenue was $82.58 billion, an increase of 0.64% compared to the previous year's $82.06 billion. Earnings were $14.71 billion, a decrease of -2.68%.
According to 19 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is 187.39, which is an increase of 8.82% from the latest price.